Construction and evaluation of replication-defective recombinant optimized triosephosphate isomerase adenoviral vaccination in Schistosoma japonicum challenged mice

Vaccine

Volumn 32, Issue 7, 2014, Pages 771-778

  Dai, Yang ^a,b   Wang, Xiaoting ^b   Zhao, Song ^b   Tang, Jianxia ^b   Zhang, Lu ^c   Dai, Jianrong ^b   Zeng, Mingtao ^d   Lu, Shan ^c,e   Zhu, Yinchang ^b   Su, Chuan ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d Paul L Foster School of Medicine   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Gene optimization; Replication defective adenoviral vector; Schistosoma japonicum; Triosephosphate isomerase; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; INTERLEUKIN 17; TRIOSEPHOSPHATE ISOMERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CHINA; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SCREENING; FEMALE; GENE CONSTRUCT; GENE EXPRESSION; GENE INSERTION; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCHISTOSOMA; SCHISTOSOMA JAPONICUM; SCHISTOSOMIASIS; TH1 CELL; VACCINATION;

GENE OPTIMIZATION; REPLICATION-DEFECTIVE ADENOVIRAL VECTOR; SCHISTOSOMA JAPONICUM; TRIOSEPHOSPHATE ISOMERASE; VACCINE;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, HELMINTH; FEMALE; GENETIC VECTORS; HELMINTH PROTEINS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-17; MICE; MICE, INBRED BALB C; SCHISTOSOMA JAPONICUM; SCHISTOSOMIASIS JAPONICA; TH1 CELLS; TH2 CELLS; TRIOSE-PHOSPHATE ISOMERASE; VACCINATION; VACCINES;

EID: 84892900849     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.12.059     Document Type: Article

References (67)

1. Gryseels B. Schistosomiasis. Infect Dis Clin North Am 2012, 26:383-397.
2. Schistosomiasis: number of people treated in 2011. Wkly Epidemiol Rec 2013, 88:81-88.
3. Gryseels B., Polman K., Clerinx J., Kestens L. Human schistosomiasis. Lancet 2006, 368:1106-1118.
4. Zheng Q., Vanderslott S., Jiang B., Xu L.L., Liu C.S., Huo L.L., et al. Research gaps for three main tropical diseases in the People's Republic of China. Infect Dis Poverty 2013, 2:15.
5. Liu R., Dong H.F., Jiang M.S. The new national integrated strategy emphasizing infection sources control for schistosomiasis control in China has made remarkable achievements. Parasitol Res 2013, 112:1483-1491.
6. Zheng H., Zhang L.J., Zhu R., Xu J., Li S.Z., Guo J.G., et al. Schistosomiasis situation in People's Republic of China in 2011. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi 2012, 24:621-626. [Article in Chinese].
7. Gray D.J., Williams G.M., Li Y., McManus D.P. Transmission dynamics of Schistosoma japonicum in the lakes and marshlands of China. PLoS ONE 2008, 3:e4058.
8. Gray D.J., Williams G.M., Li Y., Chen H., Forsyth S.J., Li R.S., et al. A cluster-randomized intervention trial against Schistosoma japonicum in the Peoples' Republic of China: bovine and human transmission. PLoS ONE 2009, 4:e5900.
9. Hong X.C., Xu X.J., Chen X., Li Y.S., Yu C.H., Yuan Y., et al. Assessing the effect of an integrated control strategy for schistosomiasis japonica emphasizing bovines in a marshland area of Hubei Province, China: a cluster randomized trial. PLoS Negl Trop Dis 2013, 7:e2122.
10. Bergquist R., Utzinger J., McManus D.P. Trick or treat: the role of vaccines in integrated schistosomiasis control. PLoS Negl Trop Dis 2008, 2:e244.
11. McManus D.P. Prospects for development of a transmission blocking vaccine against Schistosoma japonicum. Parasite Immunol 2005, 27:297-308.
12. Gray D.J., Williams G.M., Li Y.S., Chen H.G., Li R.S., Forsyth S.J., et al. A cluster-randomized bovine intervention trial against Schistosoma japonicum in the People's Republic of China: design and baseline results. Am J Trop Med Hyg 2007, 77:866-874.
13. Rudge J.W., Webster J.P., Lu D.B., Wang T.P., Fang G.R., Basáñez M.G. Identifying host species driving transmission of schistosomiasis japonica, a multihost parasite system, in China. Proc Natl Acad Sci U S A 2013, 110:11457-11462.
14. Chen M.G. Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years' experience. Acta Trop 2005, 96:168-176.
15. Wu W., Huang Y. Application of praziquantel in schistosomiasis japonica control strategies in China. Parasitol Res 2013, 112:909-915.
16. Wang W., Wang L., Liang Y.S. Susceptibility or resistance of praziquantel in human schistosomiasis: a review. Parasitol Res 2012, 111:1871-1877.
17. Seto E.Y., Wong B.K., Lu D., Zhong B. Human schistosomiasis resistance to praziquantel in China: should we be worried. Am J Trop Med Hyg 2011, 85:74-82.
18. Bergquist N.R., Leonardo L.R., Mitchell G.F. Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approachα. Trends Parasitol 2005, 21(3):112-117.
19. He Y.X., Salafsky B., Ramaswamy K. Host-parasite relationships of Schistosoma japonicum in mammalian hosts. Trends Parasitol 2001, 17:320-324.
20. Lin D., Tian F., Wu H., Gao Y., Wu J., Zhang D., et al. Multiple vaccinations with UV-attenuated cercariae in pig enhance protective immunity against Schistosoma japonicum infection as compared to single vaccination. Parasites Vectors 2011, 4:103.
21. Liu S., Song G., Xu Y., Yang W., McManus D.P. Immunization of mice with recombinant Sjc26GST induces a pronounced anti-fecundity effects after experimental with Chinese Schistosoma japonicum. Vaccine 1995, 13:603-607.
22. Zhu Y., Si J., Harn D.A., Yu C., Liang Y., Ren J., et al. The protective immunity of a DNA vaccine encoding Schistosoma japonicum Chinese strain triosephosphate isomerase in infected BALB/c mice. Southeast Asian J Trop Med Public Health 2004, 35:518-522.
23. Liu J.M., Cai X.Z., Lin J.J., Fu Z.Q., Yang G.Z., Shi F.H., et al. Gene cloning, expression and vaccine testing of Schistosoma japonicum SjFABP. Parasite Immunol 2004, 26:351-358.
24. Zhu Y., Ren J., Harn D.A., Si J., Yu C., Ming X., et al. Protective immunity induced with 23kDa membrane protein DNA vaccine of Schistosoma japonicum Chinese strain in infected C57BL/6 mice. Southeast Asian J Trop Med Public Health 2003, 34:697-701.
25. Yuan H., You-En S., Long-Jiang Y., Xiao-Hua Z., Liu-Zhe L., Cash M., et al. Studies on the protective immunity of Schistosoma japonicum bivalent DNA vaccine encoding Sj23 and Sj14. Exp Parasitol 2007, 115:379-386.
26. Dai Y., Zhu Y., Harn D.A., Wang X., Tang J., Zhao S., et al. DNA vaccination by electroporation and boosting with recombinant proteins enhances the efficacy of DNA vaccines for schistosomiasis japonica. Clin Vaccine Immunol 2009, 16:1796-1803.
27. Zhu Z., Fu Z., Zhang M., Han Y., Hong Y., Li D., et al. Protective efficacy evaluation induced by recombinant protein LHD-Sj23-GST of Schistosoma japonicum emulsified with three different adjuvants. Parasite Immunol 2012, 34:341-344.
28. Chen G., Dai Y., Chen J., Wang X., Tang B., Zhu Y., et al. Oral delivery of the Sj23LHD-GST antigen by Salmonella typhimurium type III secretion system protects against Schistosoma japonicum infection in mice. PLoS Negl Trop Dis 2011, 5:e1313.
29. Li M.J., Lei J.H., Wang T., Lu S.J., Guan F., Liu W.Q., et al. Cimetidine enhances the protective effect of GST DNA vaccine against Schistosoma japonicum. Exp Parasitol 2011, 128:427-432.
30. Zhou Y., Zhang H., Sun X.J., Zheng D., Liang Y.J., Luo J., et al. Murine CD8(+)T cell cytotoxicity against schistosomula induced by inoculation of schistosomal 22.6/26GST coupled Sepharose 4B beads. Vaccine 2012, 30:2440-2447.
31. Breyer B., Jiang W., Cheng H., Zhou L., Paul R., Feng T., et al. Adenoviral vector-mediated gene transfer for human gene therapy. Curr Gene Ther 2001, 1:149-162.
32. Nadeau I., Kamen A. Production of adenovirus vector for gene therapy. Biotechnol Adv 2003, 20:475-489.
33. McConnell M.J., Imperiale M.J. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 2004, 15:1022-1033.
34. Goodman A.L., Blagborough A.M., Biswas S., Wu Y., Hill A.V., Sinden R.E., et al. A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity. PLoS ONE 2011, 6:e29428.
35. Tchilian E., Ahuja D., Hey A., Jiang S., Beverley P. Immunization with different formulations of Mycobacterium tuberculosis antigen 85A induces immune responses with different specificity and protective efficacy. Vaccine 2013, 31:4624-4631.
36. Richardson J.S., Abou M.C., Tran K.N., Kumar A., Sahai B.M., Kobinger G.P. Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs. J Infect Dis 2011, 204:S1032-S1042.
37. Novak R.M., Metch B., Buchbinder S., Cabello R., Donastorg Y., Figoroa J.P., et al. Risk behavior among women enrolled in a randomized controlled efficacy trial of an adenoviral vector vaccine to prevent HIV acquisition. AIDS 2013, 27:1763-1770.
38. Pandey J.P., Namboodiri A.M., Bu S., De Dieu Tapsoba J., Sato A., Dai J.Y. Immunoglobulin genes and the acquisition of HIV infection in a randomized trial of recombinant adenovirus HIV vaccine. Virology 2013, 441:70-74.
39. Zhu Y., Lu F., Dai Y., Wang X., Tang J., Zhao S., et al. Synergistic enhancement of immunogenicity and protection in mice against Schistosoma japonicum with codon optimization and electroporation delivery of SjTPI DNA vaccines. Vaccine 2010, 28:5347-5355.
40. Luo J., Deng Z.L., Luo X., Tang N., Song W.X., Chen J., et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc 2007, 2:1236-1247.
41. Yu C.X., Zhu Y.C., Yin X.R., Hua W.Q., Si J., Guan X.H. Expression and characterization of recombinant triosephosphate isomerase (rTPI) of Schistosoma japonicum Chinese strain. Chinese J Zoonoses 1999, 15:31-33. [article in Chinese].
42. Bonyadi M.R., Bastani P. Modification and evaluation of avidity IgG testing for differentiating of Toxoplasma gondii infection in early stage of pregnancy. Cell J 2013, 15:238-243.
43. Saroja Ch., Lakshmi P., Bhaskaran S. Recent trends in vaccine delivery systems: a review. Int J Pharm Investig 2011, 1:64-74.
44. Koblin B.A., Casapia M., Morgan C., Qin L., Wang Z.M., Defawe O.D., et al. Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial. PLoS ONE 2011, 6:e24517.
45. Jun S., Clapp B., Zlotkowska D., Hoyt T., Holderness K., Maddaloni M., et al. Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication. Int Immunol 2012, 24:117-128.
46. Roy C.J., Ault A., Sivasubramani S.K., Gorres J.P., Wei C.J., Andersen H., et al. Aerosolized adenovirus-vectored vaccine as an alternative vaccine delivery method. Respir Res 2011, 12:153.
47. Mercier G.T., Nehete P.N., Passeri M.F., Nehete B.N., Weaver E.A., Templeton N.S., et al. Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine 2007, 25:8687-8701.
48. De Rose R., Tennent J., McWaters P., Chaplin P.J., Wood P.R., Kimpton W., et al. Efficacy of DNA vaccination by different routes of immunization in sheep. Vet Immunol Immunopathol 2002, 90:55-63.
49. Wang S., Zhang C., Zhang L., Li J., Huang Z., Lu S. The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine 2008, 26:2100-2110.
50. Mohanan D., Slütter B., Henriksen-Lacey M., Jiskoot W., Bouwstra J.A., Perrie Y., et al. Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J Control Release 2010, 147:342-349.
51. McCluskie M.J., Brazolot Millan C.L., Gramzinski R.A., Robinson H.L., Santoro J.C., Fuller J.T., et al. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol Med 1999, 5:287-300.
52. Tian F., Lin D., Wu J., Gao Y., Zhang D., Ji M., et al. Immune events associated with high level protection against Schistosoma japonicum infection in pigs immunized with UV-attenuated cercariae. PLoS ONE 2010, 5:e13408.
53. Hewitson J.P., Hamblin P.A., Mountford A.P. Immunity induced by the radiation-attenuated schistosome vaccine. Parasite Immunol 2005, 27:271-280.
54. McWilliam H.E., Piedrafita D., Li Y., Zheng M., He Y., Yu X., et al. Local immune responses of the Chinese water buffalo, Bubalus bubalis, against Schistosoma japonicum larvae: crucial insights for vaccine design. PLoS Negl Trop Dis 2013, 7:e2460.
55. Xiang Z.Q., Gao G.P., Reyes-Sandoval A., Li Y., Wilson J.M., Ertl H.C. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol 2003, 77:10780-10789.
56. Cheng X., Ming X., Croyle M.A. PEGylated adenoviruses for gene delivery to the intestinal epithelium by the oral route. Pharm Res 2003, 20:1444-1451.
57. Scallan C.D., Tingley D.W., Lindbloom J.D., Toomey J.S., Tucker S.N. An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin Vaccine Immunol 2013, 20:85-94.
58. Yu J.J., Ruddy M.J., Wong G.C., Sfintescu C., Baker P.J., Smith J.B., et al. An essential role for IL-17 in preventing pathogen-initiated bone destruction: recruitment of neutrophils to inflamed bone requires IL-17 receptor-dependent signals. Blood 2007, 109:3794-3802.
59. Chung D.R., Kasper D.L., Panzo R.J., Chitnis T., Grusby M.J., Sayegh M.H., et al. CD4+ T cells mediate abscess formation in intra-abdominal sepsis by an IL-17-dependent mechanism. J Immunol 2003, 170:1958-1963.
60. Rutitzky L.I., Stadecker M.J. CD4 T cells producing pro-inflammatory interleukin-17 mediate high pathology in schistosomiasis. Mem Inst Oswaldo Cruz 2006, 101:327-330.
61. Rutitzky L.I., Smith P.M., Stadecker M.J. T-bet protects against exacerbation of schistosome egg-induced immunopathology by regulating Th17-mediated inflammation. Eur J Immunol 2009, 39:2470-2481.
62. Abdul-Ghani R.A., Hassan A.A. Murine schistosomiasis as a model for human schistosomiasis mansoni: similarities and discrepancies. Parasitol Res 2010, 107:1-8.
63. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGF beta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
64. Zhou L., Ivanov I.I., Spolski R., Min R., Shenderov K., Egawa T., et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007, 8:967-974.
65. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
66. Lee Y.K., Mukasa R., Hatton R.D., Weaver C.T. Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol 2009, 21:274-280.
67. Wen X., He L., Chi Y., Zhou S., Hoellwarth J., Zhang C., et al. Dynamics of Th17 cells and their role in Schistosoma japonicum infection in C57BL/6 mice. PLoS Negl Trop Dis 2011, 5:e1399.